1006899-23-5

Basic information

• Product Name: 4-amino-2-cyclopropylbenzonitrile
• Synonyms: 4-amino-2-cyclopropylbenzonitrile
• CAS NO: 1006899-23-5
• Molecular Weight: 158.203
• Mol File: 1006899-23-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-amino-2-cyclopropylbenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-2-cyclopropylbenzonitrile(1006899-23-5)
• EPA Substance Registry System: 4-amino-2-cyclopropylbenzonitrile(1006899-23-5)

Safety Data

• Hazardous Substances Data: 1006899-23-5(Hazardous Substances Data)

Upstream product

• 100-01-6 4-nitro-aniline 
• 13296-94-1 2-bromo-4-nitroaniline 
• 34662-35-6 2-bromo-4-nitrobenzonitrile 
• 1533425-12-5 2-cyclopropyl-4-nitrobenzonitrile 
• 28163-00-0 4-nitro-2-chlorobenzonitrile 
• 20925-27-3 4-amino-2-chlorobenzonitrile 
• 411235-57-9 cyclopropylboronic acid 

Downstream Products

• 1533425-13-6 2-cyclopropyl-4-isothiocyanatobenzonitrile 
• 1533434-91-1 (Z)-methyl N'-cyano-N-(4-cyano-3-cyclopropylphenyl)carbamimidothioate 
• 1533424-23-5 4-(5-amino-1H-1,2,4-triazol-3-ylamino)-2-cyclopropylbenzonitrile 

Relevant articles and documents

NOVEL COMPOUNDS

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof

The invention relates to compounds of formula (I) wherein the groups R and R′, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.

FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION

Disclosed are fused heterocyclic compounds of Formula (I) or pharmaceutically-acceptable salts or stereoisomers thereof. Also disclosed are methods of using such compounds in the treatment of at least one androgen receptor-associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.